Open-label, Randomized, Single-dose, Cross-over Study to Assess Bioequivalence Between a Single 120 mg Nifurtimox Tablet and a Newly Developed 120 mg Nifurtimox Tablet, Administered Orally Under Fed Conditions to Adult Male and Female Patients With Chronic Chagas' Disease
Phase of Trial: Phase I
Latest Information Update: 07 Nov 2019
Price : $35 *
At a glance
- Drugs Nifurtimox (Primary)
- Indications Chagas disease
- Focus Pharmacokinetics
- Sponsors Bayer
- 24 Jun 2019 Status changed from active, no longer recruiting to completed.
- 23 Apr 2019 Status changed from recruiting to active, no longer recruiting.
- 22 Mar 2019 Planned End Date changed from 21 Jun 2019 to 7 Jun 2019.